Goals
Our research is driven by one fundamental question: what enables metastasis? We will investigate and understand how the tumor microenvironment orchestrates metastatic progression. Specifically, we will explore the dynamic interplay between the tumor vasculature and the tumor matrisome and how their reprogramming generates microenvironmental cues that facilitate metastatic progression. Through this knowledge, we aim to identify new markers for diagnostics development and therapeutic targeting.
At the heart of our work is the commitment to local relevance and scientific equity. Part of our research will also involve establishing primary cancer cell lines derived from patients in our region, a significant step towards building relevant research tools that reflect underrepresented populations in global cancer research. These patient-derived cancer cells provide a powerful platform to uncover under researched (epi)genetic variants, context-specific mechanisms of metastasis, and cancer drug resistance, which will generate groundbreaking insights that can be translated into clinical efficacy.
Projects
Vascular maturation and stabilization, herein referred to as vascular normalization, is a therapeutic approach associated with transformation of chaotic, immature and leaky vessels into functional systems. This often leads to reduced tumor hypoxia, improved treatment response, and increased immune response. In hypervascular tumors such as clear cell renal cell carcinoma (ccRCC), there is a significant correlation between endothelial markers, vascular stabilization genes and patient survival. Paradoxically, in low grade gliomas (LGG), high expression of endothelial markers, associated with hypervascularity, correlate with poor patient survival. The aim of this research is to understand how vessel normalization in LGG shapes the tumor microenvironment and its subsequent contribution to disease progression.
Matrisome remodeling is a primary hallmark of colon adenocarcinoma (COAD) and is associated with aggressive disease and poor clinical outcomes. Biglycan, a proteoglycan and a member of the matrisome, is highly expressed in COAD and significantly correlates with survival outcomes. However, how biglycan expression shapes the COAD matrisome remains unknown.
Lung cancer is among the leading causes of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) accounts for over 85% of all lung cancers, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) being the most dominant subtypes. While both diseases affect the lung, they originate from different regions with LUAD arising from the alveolar epithelial cells and LUSC from the bronchial epithelium. NSCLC progression is associated with extensive matrisome remodeling, which promote distant metastasis and therapy resistance. We aim to characterize stage-specific matrisome changes in NSCLC, identify prognostic ECM signatures, and compare subtype-specific matrisome remodeling patterns with relevance to lung cancer management in Kenya.
Glioblastoma (GBM) and clear cell renal cell carcinoma (ccRCC) are two of the most highly vascularized solid tumors, driven by extensive microvascular proliferation and VHL/HIF pathway activation, respectively. While both tumors show robust angiogenesis, the regulatory role of angiogenic signaling on the tumor matrisome remains unclear. Second, whether angiogenesis-driven matrisome changes is conserved across both tumor types is also unknown. The study will provide the first comparative insight into angiogenesis-mediated matrisome remodeling to elucidate mechanisms underlying disease progression and therapeutic vulnerabilities.
The endothelial secretome is an important regulator of tissue homeostasis as well as angiogenesis and tumor progression. Our previous study (PMID: 41102702) showed significant matrisome alterations between normal endothelial cells (NEC) and tumor endothelial cells (TEC) under standard culture conditions. Yet, hypoxia (low oxygen availability) is a hallmark of solid tumors and potential regulator of endothelial function, and specifically important in the tumor microenvironment. This project will conduct an in-depth computational re-analysis of secretome data of NEC and TEC under normoxia and hypoxia, identifying condition-specific and cell-type specific secretome alterations, with emphasis on the matrisome. This work will contribute to understanding how hypoxia shapes the endothelial secretome/matrisome, elucidating specific pathways and mechanism relevant to tumor progression.
YAP/TAZ, the transcriptional regulators of the Hippo pathway, are implicated in mechanotransduction and fibrosis in pancreatic ductal adenocarcinoma (PDAC) tumors. However, their relationship with the global matrisome signature has not been characterized in either bulk or single-cell PDAC data sets. While PDAC is generally desmoplastic, which is usually driven by cancer associated fibroblasts (CAFs), there is a dearth of knowledge about a distinct YAP/TAZ-driven matrisome signature and its contribution to disease progression, distant metastasis, and therapeutic sensitivity
Funding
The Oria Lab is supported by a mix of institutional and project-based funding. Partner and funder acknowledgements are listed on relevant project and resource pages.
We are open to collaborations.
